Acadia Pharmaceuticals (ACAD) Net Equity Issued and Repurchased (2010 - 2026)

Acadia Pharmaceuticals' Net Equity Issued and Repurchased history runs 17 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased rose 130.2% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $52.3 million, a 584.24% increase from a year earlier, with the FY2025 full-year figure at $49.9 million, up 628.75% from the prior year.
• Net Equity Issued and Repurchased retreated to $4.2 million in Q1 2026 per ACAD's latest filing, from $22.7 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $22.7 million in Q4 2025 and bottomed at $268000.0 in Q3 2024.
• The 5-year median for Net Equity Issued and Repurchased is $3.6 million (2024), against an average of $5.5 million.
• Across the five-year window, Net Equity Issued and Repurchased jumped 4342.86% in 2023 and slumped 97.9% in 2024, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $1.6 million in 2022, then surged by 236.68% to $5.4 million in 2023, then tumbled by 63.77% to $2.0 million in 2024, then soared by 1051.14% to $22.7 million in 2025, then tumbled by 81.33% to $4.2 million in 2026.
• Per Business Quant, the three latest ACAD Net Equity Issued and Repurchased figures stand at $4.2 million (Q1 2026), $22.7 million (Q4 2025), and $9.4 million (Q3 2025).